Clinuvel Pharmaceuticals announced yesterday that Scenesse has been granted Priority Review by the FDA - the New Drug Application will be reviewed by July 8, 2019. Visit www.clinuvel.com for full information.
The APF and you, the patient community, have been relentless in pursuit of this treatment. Writing letters, making calls, signing petitions, sending photographs, attending meetings - it worked!
We will continue to focus on this until this treatment is approved and available to all EPP patients in the US.